期刊
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
卷 192, 期 6, 页码 1905-1912出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.ajog.2005.02.052
关键词
fragile X screening; cost-effectiveness analysis; prenatal genetic screening
资金
- NICHD NIH HHS [HD01262] Funding Source: Medline
Objective: To investigate the cost-effectiveness of a widespread prenatal population-based fragile X carrier screening program. Study design: A decision tree was designed comparing screening versus not screening for the fragile X mental retardation protein 1 premutation in all pregnant women. Baseline values included a prevalence of fragile X mental retardation protein 1 premutations of 3.3 per 1000, a premutation expansion rate of 11.3%, and a 99% sensitivity of the screening test. The cost of the screening test was varied from $75 to $300. A sensitivity analysis of the probabilities, utilities, and costs was performed. Results: The screening strategy Would lead to the identification of 80% of the fetuses affected by fragile X annually. Assuming the cost of $95 per test and only one child, the program would be cost effective at $14,858 per quality-adjusted life-year. The screening strategy remained cost effective up to $140 per test and 1 child per woman or for 2 children per woman up to a cost of $281 per test. Conclusion: population-based screening for the fragile X premutation may be both clinically desirable and cost effective. Prospective pilot studies of this screening modality are needed in the prenatal setting. (c) 2005 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据